Savannah, Georgia, U.S.A., September 2-5, 2015


ET-14 Conference Program


The Fourteenth International Conference on Endothelin (ET-14: September 2-5, 2015, Hyatt Regency Savannah Hotel, Savannah, GA, USA.


Download ET-14 Program and Abstract Booklet here




____________________________________

Wednesday, September 2, 2015




Registration
Wednes., 3:00 PM

Welcome Address and Opening Reception
Wednes., 6:00-8:00 PM, Harborside Center East (street level of hotel)


__________________________________

Thursday, September 3, 2015


SYMPOSIA I: NOVEL ASPECTS OF THE ENDOTHELIN SYSTEM
Thurs., 8:00—10:00 AM, Ballroom A.

Chairs:
Ivana Vaneckova, Inst. of Physiology, Prague, Czech Rep.
Anthony Davenport, Univ. of Cambridge, UK.

Invited Lecture:
1.1 New Insights in ET Receptor Pharmacology.
Janet Maguire.Univ. of Cambridge, UK

1.2 Identification of EDN1-AS: A Novel Long, Non-coding RNA in the Regulation of Endothelin1.
Kristin Solocinski. Univ. of Florida, Gainesville

1.3 Autocrine Endothelin 1 Signaling Promotes Osteoblast Growth and Mineral Deposition Via Induction of miR 126-3p.
Michael G. Johnson. Univ. of Wisconsin, Madison

1.4 Novel UVR-induced Melanoma Mouse Model Based on Endothelin 3 Overexpression in Conjunction with Deficiency of the Nucleotide Excision Repair Pathway.
Diana Cardero. Florida Intnl. Univ., Miami

1.5 Endothelin A Receptor Drives Invadopodia Function and Cell Motility Through β-arrestin/PDZ-RhoGEF Pathway in Ovarian Carcinoma.
Laura Rosanò. Regina Elena Natl. Cancer Inst., Rome, Italy

1.6 Early-life Stress Induces Epigenetic Reguation of the ET System in Adult Male Mice.
Dao Ho, Univ. of Alabama at Birmingham



SYMPOSIA II: THE IMMUNE SYSTEM AND ENDOTHELIN
Thurs., 10:30 AM—12:00 Noon, Ballroom A.

Chairs:
Ariela Benigni, Mario Negri Inst. for Pharmacological Res., Bergamo, Italy.
John Pernow, Karolinska Inst., Stockholm, Sweden.

Invited Lecture:
2.1 Inflammation, Immunity and Hypertension.
David Harrison. Vanderbilt Univ.

2.2 Macrophage Endothelin-B Receptors Clear Endothelin-1 & Regulate Blood Pressure.
Neeraj Dhaun. Univ. of Edinburgh, UK.

2.3 Long-term High Salt Diet Delays Development of Proteinuria in Murine Systemic Lupus Erythematosus (SLE).
Hanna Broome. Mississippi Coll., Clinton

2.4 Role of the Myeloid Endothelin-B Receptor in Angiotensin II Mediated End-organ Damage.
Lea Guyonnet, INSERM, PARCC, Paris, France


POSTER SESSION I
Thurs., 1:00—2:30 PM, Ballroom BCDEF

Odd numbered poster boards presenting. Friday: 1:00—2:30 PM, Even numbered poster boards presenting.



SYMPOSIA III: ET, SEX, AND PREGNANCY
Thurs., 2:30—4:00 PM, Ballroom A.

Chairs:
Rita Tostes, Univ. of Sao Paulo, Ribeirao Preto, Brazil.
Donald Kohan, Univ. of Utah Hlth. Sci. Ctr.

Invited Lecture:
4.1 Sex and Hypertension.
Jennifer Sullivan, Georgia Regents Univ.

4.2 Endothelin-1 (ET-1) Regulates the Expression of Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of MMPs in Human First Trimester Trophoblasts via ETB Receptor: A Possible Role in Trophoblast Invasion.
Alejandro Majali-Martinez, Med. Univ. of Graz, Austria

4.3 Attenuation of Endothelin-1-induced Cardiomyocyte Hypertrophy Through Estrogen Pretreatment.
Nobutake Shimojo, Univ. of Tsukuba, Japan

4.4 Endothelin-1: A Final Common Pathway Linking Placental Ischemia to Endothelial Dysfunction and Hypertension During Preeclampsia.
Joey Granger, Univ. of Mississippi Med. Ctr.

4.5 Endothelin Receptor Type B (ETB) Deficiency Results in Greater Blood Pressure Levels During Pregnancy and in Response to Placental Ischemia-induced Hypertension in Rats.
F. Spradley. Univ. of Mississippi Med. Ctr.



SYMPOSIA IV: ROLE OF ET IN THE VASCULATURE
Thurs., 4:30—5:30 PM, Ballroom A.

Chairs:
Joey Granger, Univ. of Mississippi Med. Ctr.
Anil Gulati, Midwestern Univ.

Invited Lecture:
5.1 ET-1 in the Heart in Health and Disease.
Noriaki Emoto, Kobe Univ., Japan.

5.2 Endothelin-1 Overexpression Exaggerates Type 1 Diabetes-induced Endothelial Dysfunction by Altering Oxidative Stress Balance.
Pierre Paradis, McGill Univ., Montreal, Canada

5.3 Linagliptin Provides Cerebrovascular Protection via Upregulation of Endothelial ET-1 and ETB Receptors in Diabetes
Mohammed Abdel-said, Georgia Regents Univ.



Trainee Mixer
Thurs., 5:30—7:00 PM, Ballroom A.

Chairs:
Kelly Hyndman, Univ. of Alabama at Birmingham.
Joshua Speed, Univ. of Alabama at Birmingham.

6.1 Endothelial-Derived Endothelin-1 Contributes to Renal Dysfunction and Mortality in Sickle Cell Mice.
Brandon Fox, Univ. of Alabama at Birmingham

6.2 Endothelin-1 Increases Glomerular Permeability in Sickle Cell Mice.
Malgorzata Kasztan, Univ. of Alabama at Birmingham.

6.3 Gender Comparison of Recovery from Intravenous and Inhalational Anaesthetics Among Adult Patients in South-West Nigeria.
Yewande Okunoren-Oyekenu. Univ. of Leicester, UK

6.4 Evaluation of Endothelin A Receptor (ETA) Blockade on the Progression of Renal Injury in Various Models of Metabolic Disorders with Pre-existing Renal Disease.
Kasi McPherson, Univ. of Mississippi Med. Ctr.

6.5 Renal Endothelin and Purinergic Systems Contribute to Sexual Dimorphism in Sodium Excretion.
Eman Y. Gohar, Univ. of Alabama at Birmingham

6.6 The Role of Endothelin System in Renal Structure and Function During the Postnatal Development of the Rat Kidney.
Maria Florencia Al- bertoni, Univ. of Buenos Aires, Argentina

6.7 TUDCA Attenuates High Salt-Induced Renal Cortical Injury in ETB Receptor Deficient Rats by Decreasing Apoptosis.
Randee Sedaka, Univ. of Alabama at Birmingham

6.8 ETA Receptor Blockade Improves the Differential Diurnal Natriuretic Response to an Acute Salt Load in Male and Female ETB Deficient Rats.
Jermaine Johnston, Univ. of Alabama at Birmingham

6.9 Hypoglycemic Effect of the Methyl Chloride-Methanolic Extract of the Fresh Fruits of the Gongronema Latifolia in Normoglycemic and Alloxan-induced Diabetic Rats.
Ifeoma Okoli, Imo State Univ., Owerri, Nigeria

6.10 Clinical use of Serum Big Endothelin-1 Levels as a Tumour Marker for Haemangiosarcoma. Shinya Fukumoto, Rakuno Gakuen Univ., Ebetsu, Japan

6.11 Treatment with DPPIV Inhibitor Linagliptin Reduces Plasma ET-1 and ET-1-induced Cerebrovascular Hyperreactivity in Diabetes.
Trevor Hardigan, Georgia Regents Univ

6.12 Endothelins as Markers of Cardiovascular Protection in Adults with Isolated Deficiency of Growth Hormone (IDGH).
Sydney Leao, Federal Univ. of São Paulo, Brazil

6.13 Endothelin 3 Regulates Pigment Production and Coat Color in Mice.
Javier Pino, Florida Intnl. Univ., Miami


______________________________

Friday, September 4, 2015



SYMPOSIA V: ENDOTHELIN AND END-ORGAN INJURY
Fri., 8:00—10:00 AM, Ballroom A.

Chairs:
Noriaki Emoto, Kobe Univ., Japan.
Matthias Barton, Univ. of Zurich, Switzerland.

Invited Lecture:
7.1 Endothelin and Diabetic Complications.
John Pernow, Karolinska Inst., Stockholm, Sweden.

7.2 Knockout of Endothelin-1 in Vascular Endothelial Cells Ameliorates Cardiac Mitochondria Dysfunction After Myocardial Infarction in Diabetes Type 2 Mice.
Hary S. Muliawan, Kobe Univ.,Japan

7.3 The Role of Endothelin in the Regulation of Blood Pressure in Early Diabetes Mellitus.
Geoff Culshaw, Univ. of Edinburgh, UK

7.4 The Endothelin System Mediates Renal Endoplasmic Reticulum Stress Development.
Carmen De Miguel. Univ. of Alabama at Birmingham

7.5 p66 Shc Regulates ET-1-mediated Intracellular Calcium Handling in Renal Resistance Arteries and Contributes to Renal Glomerular Injury in Hypertension.
Oleg Palygin, Med. Coll. of Wisconsin, Milwaukee

7.6 Renal Vascular Regeneration by Angiotensin II Antagonism is Due to Abrogation of ET- 1/ETAR Signaling.
Ariela Benigni, Inst. di Ric. Farmacol. Mario Negri, Bergamo, Italy



SYMPOSIA VI: ENDOTHELIN, ANGIOTENESIS AND VASCULAR FUNCTION
Fri., 10:30 AM—12:00 Noon, Ballroom A.

Chairs:
Anna Bagnato, Inst. Natl. Tumori Regina Elena- IFO, Rome, Italy.
Marilena Loizidou, Univ. Coll., London, UK.

Invited Lecture:
8.1 ET and Anti-angiogenic Therapy.
Anton H. van den Meiracker, Erasmus MC, Rotterdam, The Netherlands.

8.2 Endothelin-1 Stimulates Endothelial-derived Microparticle Release.
Philip J. Kavlich, Univ. of Colorado, Boulder

8.3 Endothelin Receptor Signaling and Age Related Deregulation of Cerebral Artery Myogenic Tone.
Adel Zrein, Dalhousie Univ., Halifax, Canada

8.4 High Dietary Fat Intake is Associated with Enhanced Endothelin-1 Vasoconstrictor Tone.
Caitlin Dow, Univ. of Colorado, Boulder



POSTER SESSION II

Fri., 1:00—2:30 PM, Ballroom BCDEF
Even numbered poster boards presenting.



SYMPOSIA VII: ENDOTHELIN AND FLUID- ELECTROLYTE BALANCE
Fri., 2:30—4:00 PM, Ballroom A.

Chairs:
Yasuo Matsumura, Osaka Univ. Pharma. Sci., Japan.
David M. Pollock, Univ. of Alabama at Birmingham.

Invited Lecture:
9.1 Endothelin Antagonism as a Therapeutic Strategy in Kidney Disease.
Neeraj Dhaun, Univ. of Edinburgh, UK.

9.2 Medullary Histone Deacetylase Enzymes are Critical for Water Balance During High Salt Feeding. Kelly Hyndman, Univ. of Alabama at Birmingham

9.3 Regulation of Collecting Duct Endothelin-1 Production by Flow and Osmolality.
Yang Gao, Univ. of Utah

9.4 The Role of a Renal Aldosterone-Endothelin Feedback System in Total Na Balance and Mineralocorticoid Escape.
Charles Wingo, Univ. of Florida, Gainesville

9.5 Circadian Regulation of Renal Endothelin- 1.
Joshua Speed, Univ. of Alabama at Birmingham



SYMPOSIA VIII: PULMONARY FUNCTION
Fri., 4:30—6:00 PM, Ballroom A.

Chairs:
Martine Clozel, Actelion Pharma., Ltd., Allschwil, Switzerland.
Pedro D'Orleans-Juste, Univ. of Sherbrooke, Canada.

10.1 Chronic Hypoxia in Endothelin-1 Transgenic (ETTG) Mice Generates Moderate Pulmonary Hypertension, Not Severe Pulmonary Hypertension and Its Plexiform Lesions.
Muhammed Satwiko, Kobe Univ., Japan

10.2 Postnatal Ece1 Ablation Causes Severe, Progressive Pulmonary Disease.
Jasmin Kristianto, Univ. of Wisconsin, Madison

10.3 The Evaluation of Endothelin Receptor Antagonist for Pulmonary Hypertension with Lung Disease.
Kazuhiko Nakayama, Kobe Univ. Japan


SPECIAL EVENT BANQUET
Fri., 7:00—10:00 PM, Mansion at Forsyth Park


_________________________________

Saturday, September 5, 2015


SYMPOSIA IX: CENTRAL NERVOUS SYSTEM
Sat., 8:00—10:00 AM, Ballroom A.

Chairs:
Constantino Iadecola, Weill Cornell Med. Coll.
Janet Maguire, Univ. of Cambridge, UK.

Invited Lecture:
11.1 Mechanisms of ET in Pain.
Wolfgang Liedtke, Duke Univ. Med. Ctr.

11.2 Differential Role of ETA and ETB Receptors in CNS Parameters.
Yogendra Gupta, All India Inst. of Med. Sci., New Delhi, India

11.3 Significant Contribution of the Mast Cell-derived Chymase, mMCP-4, in Early Phases of Multiple Sclerosis in Mice.
Louisane Desbiens, Univ. of Sherbrooke, Canada

11.4 The Endothelin System in Amyotrophic Lateral Sclerosis (ALS).
Lyle Ostrow, Johns Hopkins Univ. Sch. of Med.

11.5 Central Endogenous Endothelins (ETs) are Involved in the DOCA-Salt Hypertension. Interactions Between ETs Receptor A (ETA) Blockade and Tyrosine Hydroxylase (TH) in the Anterior (AH) and Posterior Hypothalamus (PH).
Maria Guil, Univ. of Buenos Aires, Argentina.

11.6 Endothelin B Receptor Agonist, IRL-1620, Provides Neuroprotection and Enhances Angiogenesis in Diabetic Rats with Cerebral Ischemia.
Anil Gulati, Midwestern Univ.



SYMPOSIA X: NOVEL INTEGRATION
Sat., 10:30 AM—12:00 Noon, Ballroom A.

Chairs:
David Webb, Univ. of Edinburgh, UK.
Adviye Ergul, Georgia Regents Univ.

Invited Lecture:
12.1 ET-1 and Neurovascular Coupling.
Constantino Iadecola, Weill Cornell Med. Coll.

12.2 Relationship of Endothelin-1 and NLRP3 Activation in HT22 Hippocampal Cells: Relevance to Cognitive Decline in Diabetes.
Rebecca Ward, Georgia Regents Univ.

12.3 Endothelin 3 Regulates Pigment Production and Coat Color in Mice.
Javier Pino, Florida Intnl. Univ., Miami

12.4 Endothelin Receptor Antagonism in Sickle Cell Nephropathy.
Olivia Lenoir, INSERM, Paris, France

12.5 ETA Receptor Blockade Inhibits Leukocyte Activation and Adhesion in Sickle Cell Disease.
D. Gutsaeva, Georgia Regents Univ.



SYMPOSIA XI: ENDOTHELIN THERAPEUTICS- WHERE ARE WE?
Sat., 1:30—3:00 PM, Ballroom A.

Chairs:
Jennifer S. Pollock, Univ. of Alabama at Birmingham.
Jennifer Sullivan, Georgia Regents Univ.

13.1 Endothelin Therapeutics in Cancer - Where Are We?
Anna Bagnato, Inst. Natl. Tumori Regina Elena-IFO, Rome, Italy.

13.2 Endothelin Antagonists in Diabetic Nephropathy.
Donald Kohan, Univ. of Utah Hlth. Sci. Ctr.

13.3 Endothelin Antagonism, Where Next?
Pierre-Louis Tharaux, INSERM, Paris, France.

13.4 Review of Clinical Development of Sparsentan, a Dual-acting Angiotensin and Endothelin Receptor Antagonist.
Radko Komers, Retrophin, Inc., Cambridge, MA.

13.5 Endothelin Research and Drug Discovery.
Martine Clozel, Actelion Pharma., Ltd., Allschwil, Switzerland.



CONFERENCE SUMMARY AND HIGHLIGHTS
Sat., 3:30—4:30 PM, Ballroom A.

Panelists:
Ariela Benigni, Mario Negri Inst. for Pharma. Res., Bergamo, Italy
Pedro D'Orleans-Juste, Univ. of Sherbrooke, Canada.
Anthony Davenport, Univ.of Cambridge, UK. David Webb, Univ. of Edinburgh, UK.
Masashi Yanagisawa, Univ. of Tsukuba, Japan.